Document is current
Any future updates will be listed below
-
Authors
Serrar, Yasmine https://orcid.org/0000-0001-6593-4064
Sejournet, Lucas https://orcid.org/0000-0003-4395-5918
Thomeret, Victor https://orcid.org/0009-0000-6153-3028
Dot, Corinne https://orcid.org/0000-0003-4398-3978
Bonnin, Sophie https://orcid.org/0000-0003-2614-9412
Soler, Vincent https://orcid.org/0000-0002-3837-0619
Rosier, Laurence
Matonti, Frédéric https://orcid.org/0000-0002-6180-3937
Ghazaryan, Mariam https://orcid.org/0000-0001-8842-1755
Mathis, Thibaud https://orcid.org/0000-0002-1418-1872
Kodjikian, Laurent https://orcid.org/0000-0002-3908-6716
- License Information
-
More Information
Article History
Received: 8 February 2025
Revised: 29 May 2025
Accepted: 3 July 2025
First Online: 21 July 2025
Competing interests
: YS, LS, VT and MG have no conflict of interest to report. LK is consultant for Abbvie, Astellas, Bayer, Alimera-Horus, Novartis, Roche and Théa. TM is consultant for Abbvie, Astellas, Bayer, Horus, Novartis and Roche. CD is consultant for Abbvie, Bayer, Horus, Novartis, Roche and Thea. SB is consultant for AbbVie, Bayer, Oculis, Optic 2000, Roche. VS is consultant for Abbvie, Alcon, FCI, Bayer, Cristallens, Horus, Roche, Novartis and Thea. LR is consultant for Abbvie, Bayer, Horus Novartis and Roche. FM is consultant for Abbvie, Bayer, Alimera-Horus, Roche, and Novartis.
